Radiation Oncology Journal

The Korean Society for Radiation Oncology (대한방사선종양학회)
권호 표지
DOI QR코드

DOI QR Code

National trends in radiation dose escalation for glioblastoma

  • Wegner, Rodney E. (Division of Radiation Oncology, Allegheny Health Network Cancer Institute) ;
  • Abel, Stephen (Division of Radiation Oncology, Allegheny Health Network Cancer Institute) ;
  • Horne, Zachary D. (Division of Radiation Oncology, Allegheny Health Network Cancer Institute) ;
  • Hasan, Shaakir (Division of Radiation Oncology, Allegheny Health Network Cancer Institute) ;
  • Verma, Vivek (Division of Radiation Oncology, Allegheny Health Network Cancer Institute) ;
  • Ranjan, Tulika (Division of Medical Oncology, Allegheny Health Network Cancer Institute) ;
  • Williamson, Richard W. (Department of Neurosurgery, Allegheny Health Network) ;
  • Karlovits, Stephen M. (Division of Radiation Oncology, Allegheny Health Network Cancer Institute)
  • Received : 2019.01.04
  • Accepted : 2019.02.11
  • Published : 2019.03.31
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: Glioblastoma (GBM) carries a high propensity for in-field failure despite trimodality management. Past studies have failed to show outcome improvements with dose-escalation. Herein, we examined trends and outcomes associated with dose-escalation for GBM. Materials and Methods: The National Cancer Database was queried for GBM patients who underwent surgical resection and external-beam radiation with chemotherapy. Patients were excluded if doses were less than 59.4 Gy; dose-escalation referred to doses ≥66 Gy. Odds ratios identified predictors of dose-escalation. Univariable and multivariable Cox regressions determined potential predictors of overall survival (OS). Propensity-adjusted multivariable analysis better accounted for indication biases. Results: Of 33,991 patients, 1,223 patients received dose-escalation. Median dose in the escalation group was 70 Gy (range, 66 to 89.4 Gy). The use of dose-escalation decreased from 8% in 2004 to 2% in 2014. Predictors of escalated dose were African American race, lower comorbidity score, treatment at community centers, decreased income, and more remote treatment year. Median OS was 16.2 months and 15.8 months for the standard and dose-escalated cohorts, respectively (p = 0.35). On multivariable analysis, age >60 years, higher comorbidity score, treatment at community centers, decreased education, lower income, government insurance, Caucasian race, male gender, and more remote year of treatment predicted for worse OS. On propensity-adjusted multivariable analysis, age >60 years, distance from center >12 miles, decreased education, government insurance, and male gender predicted for worse outcome. Conclusion: Dose-escalated radiotherapy for GBM has decreased over time across the United States, in concordance with guidelines and the available evidence. Similarly, this large study did not discern survival improvements with dose-escalation.

Keywords

References

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018;68:7-30. https://doi.org/10.3322/caac.21442
  2. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTCNCIC trial. Lancet Oncol 2009;10:459-66. https://doi.org/10.1016/S1470-2045(09)70025-7
  3. Dobelbower MC, Burnett Iii OL, Nordal RA, et al. Patterns of failure for glioblastoma multiforme following concurrent radiation and temozolomide. J Med Imaging Radiat Oncol 2011;55:77-81. https://doi.org/10.1111/j.1754-9485.2010.02232.x
  4. Gebhardt BJ, Dobelbower MC, Ennis WH, Bag AK, Markert JM, Fiveash JB. Patterns of failure for glioblastoma multiforme following limited-margin radiation and concurrent temozolomide. Radiat Oncol 2014;9:130. https://doi.org/10.1186/1748-717X-9-130
  5. Minniti G, Amelio D, Amichetti M, et al. Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide. Radiother Oncol 2010;97:377-81. https://doi.org/10.1016/j.radonc.2010.08.020
  6. Badiyan SN, Markovina S, Simpson JR, et al. Radiation therapy dose escalation for glioblastoma multiforme in the era of temozolomide. Int J Radiat Oncol Biol Phys 2014;90:877-85. https://doi.org/10.1016/j.ijrobp.2014.07.014
  7. Souhami L, Seiferheld W, Brachman D, et al. Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. Int J Radiat Oncol Biol Phys 2004;60:853-60. https://doi.org/10.1016/j.ijrobp.2004.04.011
  8. Tsien C, Moughan J, Michalski JM, et al. Phase I threedimensional conformal radiation dose escalation study in newly diagnosed glioblastoma: Radiation Therapy Oncology Group Trial 98-03. Int J Radiat Oncol Biol Phys 2009;73:699-708. https://doi.org/10.1016/j.ijrobp.2008.05.034
  9. Hasan S, Renz P, Turrisi A, Colonias A, Finley G, Wegner RE. Dose escalation and associated predictors of survival with consolidative thoracic radiotherapy in extensive stage small cell lung cancer (SCLC): a National Cancer Database (NCDB) propensity-matched analysis. Lung Cancer 2018;124:283-90. https://doi.org/10.1016/j.lungcan.2018.08.016
  10. Hasan S, Renz P, Wegner RE, et al. Microsatellite instability (MSI) as an independent predictor of pathologic complete response (PCR) in locally advanced rectal cancer: a National Cancer Database (NCDB) analysis. Ann Surg 2018 Sep 13 [Epub]. http://doi.org/10.1097/SLA.0000000000003051.
  11. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-9. https://doi.org/10.1016/0895-4356(92)90133-8
  12. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81. https://doi.org/10.1080/01621459.1958.10501452
  13. Cox DR. Regression models and life-tables. J R Stat Soc Series B Stat Methodol 1972;34:187-202.
  14. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998;17:2265-81. https://doi.org/10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B
  15. Black PM. Brain tumors. Part 1. N Engl J Med 1991;324:1471-6. https://doi.org/10.1056/NEJM199105233242105
  16. McNeill KA. Epidemiology of brain tumors. Neurol Clin 2016;34:981-98. https://doi.org/10.1016/j.ncl.2016.06.014
  17. Cardinale R, Won M, Choucair A, et al. A phase II trial of accelerated radiotherapy using weekly stereotactic conformal boost for supratentorial glioblastoma multiforme: RTOG 0023. Int J Radiat Oncol Biol Phys 2006;65:1422-8. https://doi.org/10.1016/j.ijrobp.2006.02.042
  18. Reddy K, Gaspar LE, Kavanagh BD, Chen C. Hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy may alter the patterns of failure in patients with glioblastoma multiforme. J Med Imaging Radiat Oncol 2014;58:714-21. https://doi.org/10.1111/1754-9485.12185
  19. Torok JA, Wegner RE, Mintz AH, Heron DE, Burton SA. Reirradiation with radiosurgery for recurrent glioblastoma multiforme. Technol Cancer Res Treat 2011;10:253-8. https://doi.org/10.7785/tcrt.2012.500200
  20. Hasan S, Chen E, Lanciano R, et al. Salvage fractionated stereotactic radiotherapy with or without chemotherapy and immunotherapy for recurrent glioblastoma multiforme: a single institution experience. Front Oncol 2015;5:106. https://doi.org/10.3389/fonc.2015.00106
  21. Gigliotti MJ, Hasan S, Karlovits SM, Ranjan T, Wegner RE. Re-irradiation with stereotactic radiosurgery/radiotherapy for recurrent high-grade gliomas: improved survival in the modern era. Stereotact Funct Neurosurg 2018;96:289-95. https://doi.org/10.1159/000493545
  22. Verma V, Mehta MP. Clinical ramifications of "genomic staging" of low-grade gliomas. J Neurooncol 2016;129:195-9. https://doi.org/10.1007/s11060-016-2192-z
  23. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:997-1003. https://doi.org/10.1056/NEJMoa043331
  24. Tini P, Nardone V, Pastina P, et al. Patients affected by unmethylated O(6)-methylguanine-DNA methyltransferase glioblastoma undergoing radiochemotherapy may benefit from moderately dose-escalated radiotherapy. Biomed Res Int 2017;2017:9461402.

Cited by

  1. Presentation of treatment effect in glioblastoma after dose-escalation radiation therapy vol.2019, pp.9, 2019, https://doi.org/10.1093/omcr/omz085
  2. Trimodality therapy for atypical teratoid/rhabdoid tumor is associated with improved overall survival: A surveillance, epidemiology, and end results analysis vol.66, pp.12, 2019, https://doi.org/10.1002/pbc.27969
  3. Longitudinal analysis of quality of life following treatment with Asunercept plus reirradiation versus reirradiation in progressive glioblastoma patients vol.145, pp.3, 2019, https://doi.org/10.1007/s11060-019-03320-x
  4. Survival of glioblastoma treated with a moderately escalated radiation dose—Results of a retrospective analysis vol.15, pp.5, 2019, https://doi.org/10.1371/journal.pone.0233188
  5. Post-Operative Accelerated-Hypofractionated Chemoradiation With Volumetric Modulated Arc Therapy and Simultaneous Integrated Boost in Glioblastoma: A Phase I Study (ISIDE-BT-2) vol.10, 2019, https://doi.org/10.3389/fonc.2020.626400
  6. Novel Treatment for Glioblastoma Delivered by a Radiation Responsive and Radiopaque Hydrogel vol.7, pp.7, 2021, https://doi.org/10.1021/acsbiomaterials.1c00385